Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Details Narrative)

v3.20.2
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Mar. 19, 2018
Amortization expense $ 198,832 $ 198,832 $ 596,496 $ 596,496  
Future amortization expense $ 790,000   $ 790,000    
CoNCERT Pharmaceuticals, Inc [Member] | License Rights [Member]          
Purchase price         $ 8,000,000
Transaction cost         1,782
Recognition of deferred tax liability         3,037,147
Intangible asset, tax basis         $ 1,782